Literature DB >> 25937437

Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010.

Robert D Allison1, Xin Tong2, Anne C Moorman2, Kathleen N Ly2, Loralee Rupp3, Fujie Xu2, Stuart C Gordon3, Scott D Holmberg2.   

Abstract

BACKGROUND & AIMS: Persons chronically infected with the hepatitis C virus (HCV) may be at higher risk for developing and dying from non-liver cancers than the general population.
METHODS: 12,126 chronic HCV-infected persons in the Chronic Hepatitis Cohort Study (CHeCS) contributed 39,984 person-years of follow-up from 2006 to 2010 and were compared to 133,795,010 records from 13 Surveillance, Epidemiology and End Results Program (SEER) cancer registries, and approximately 12 million U.S. death certificates from Multiple Cause of Death (MCOD) data. Measurements included standardized rate ratios (SRR) and relative risk (RR).
RESULTS: The incidence of the following cancers was significantly higher among patients with chronic HCV infection: liver (SRR, 48.6 [95% CI, 44.4-52.7]), pancreas (2.5 [1.7-3.2]), rectum (2.1 [1.3-2.8]), kidney (1.7 [1.1-2.2]), non-Hodgkin lymphoma (NHL) (1.6 [1.2-2.1]), and lung (1.6 [1.3-1.9]). Age-adjusted mortality was significantly higher among patients with: liver (RR, 29.6 [95% CI, 29.1-30.1]), oral (5.2 [5.1-5.4]), rectum (2.6 [2.5-2.7]), NHL (2.3 [2.2-2.31]), and pancreatic (1.63 [1.6-1.7]) cancers. The mean ages of cancer diagnosis and cancer-related death were significantly younger among CHeCS HCV cohort patients compared to the general population for many cancers.
CONCLUSIONS: Incidence and mortality of many types of non-liver cancers were higher, and age at diagnosis and death younger, in patients with chronic HCV infection compared to the general population. Published by Elsevier B.V.

Entities:  

Keywords:  Cancer; Hepatitis C virus; Incidence; Mortality; SEER

Mesh:

Year:  2015        PMID: 25937437      PMCID: PMC5675515          DOI: 10.1016/j.jhep.2015.04.021

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  35 in total

1.  Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma.

Authors:  E Zuckerman; T Zuckerman; A M Levine; D Douer; K Gutekunst; M Mizokami; D G Qian; M Velankar; B N Nathwani; T L Fong
Journal:  Ann Intern Med       Date:  1997-09-15       Impact factor: 25.391

2.  Hepatitis C in the United States.

Authors:  Scott D Holmberg; Philip R Spradling; Anne C Moorman; Maxine M Denniston
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

3.  Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection.

Authors:  D Sansonno; G Lauletta; M Montrone; G Grandaliano; F P Schena; F Dammacco
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

4.  Prevalence and epidemiology of hepatitis C virus in patients with squamous cell carcinoma of the head and neck.

Authors:  James Nobles; Christian Wold; Mary Fazekas-May; Jill Gilbert; Paul L Friedlander
Journal:  Laryngoscope       Date:  2004-12       Impact factor: 3.325

Review 5.  Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas.

Authors:  Luca Arcaini; Raffaele Bruno
Journal:  Curr Clin Pharmacol       Date:  2010-05

6.  Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH.

Authors:  Alexandra Nieters; Birgit Kallinowski; Paul Brennan; Melanie Ott; Marc Maynadié; Yolanda Benavente; Lenka Foretova; Pier Luigi Cocco; Anthony Staines; Martine Vornanen; Denise Whitby; Paolo Boffetta; Nikolaus Becker; Silvia De Sanjosé
Journal:  Gastroenterology       Date:  2006-09-20       Impact factor: 22.682

7.  Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium.

Authors:  Silvia de Sanjose; Yolanda Benavente; Claire M Vajdic; Eric A Engels; Lindsay M Morton; Paige M Bracci; John J Spinelli; Tongzhang Zheng; Yawei Zhang; Silvia Franceschi; Renato Talamini; Elizabeth A Holly; Andrew E Grulich; James R Cerhan; Patricia Hartge; Wendy Cozen; Paolo Boffetta; Paul Brennan; Marc Maynadié; Pierluigi Cocco; Ramon Bosch; Lenka Foretova; Anthony Staines; Nikolaus Becker; Alexandra Nieters
Journal:  Clin Gastroenterol Hepatol       Date:  2008-04       Impact factor: 11.382

8.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

Authors:  Thomas P Giordano; Louise Henderson; Ola Landgren; Elizabeth Y Chiao; Jennifer R Kramer; Hashem El-Serag; Eric A Engels
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

9.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

Review 10.  Hepatitis C virus-related kidney disease: an overview.

Authors:  N Kamar; J Izopet; L Alric; C Guilbeaud-Frugier; L Rostaing
Journal:  Clin Nephrol       Date:  2008-03       Impact factor: 0.975

View more
  52 in total

1.  Cigarette Smoking in Persons Living with Hepatitis C: The National Health and Nutrition Examination Survey (NHANES), 1999-2014.

Authors:  Ryung S Kim; Andrea H Weinberger; Geetanjali Chander; Mark S Sulkowski; Brianna Norton; Jonathan Shuter
Journal:  Am J Med       Date:  2018-01-31       Impact factor: 4.965

2.  Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.

Authors:  Zong-Han Yao; Wei-Yu Liao; Chao-Chi Ho; Kuan-Yu Chen; Jin-Yuan Shih; Jin-Shing Chen; Zhong-Zhe Lin; Chia-Chi Lin; James Chih-Hsin Yang; Chong-Jen Yu
Journal:  Oncologist       Date:  2017-05-15

Review 3.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

4.  Antifungal-demelanizing properties and RAW264.7 macrophages stimulation of glucan sulfate from the mycelium of the mushroom Ganoderma lucidum.

Authors:  Wan Abd Al Qadr Imad Wan-Mohtar; Christina Viegelmann; Anita Klaus; Sarina Abdul Halim Lim
Journal:  Food Sci Biotechnol       Date:  2017-02-28       Impact factor: 2.391

5.  Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer.

Authors:  Minas P Economides; Moran Amit; Parag S Mahale; Jeff J Hosry; Ying Jiang; Uddalak Bharadwaj; Erich M Sturgis; Harrys A Torres
Journal:  Cancer       Date:  2017-11-17       Impact factor: 6.860

6.  The Association of Extrahepatic Cancers With Chronic Hepatitis C Virus Infection.

Authors:  Anders H Nyberg
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-03

7.  Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.

Authors:  Wei Wang; Vincent Lo Re; Yi Guo; Hong Xiao; Joshua Brown; Haesuk Park
Journal:  Aliment Pharmacol Ther       Date:  2020-09-15       Impact factor: 8.171

8.  Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfection.

Authors:  Alexander J Millman; Qingwei Luo; Noele P Nelson; Claudia Vellozzi; John Weiser
Journal:  AIDS Care       Date:  2019-09-23

9.  How I treat hepatitis C virus infection in patients with hematologic malignancies.

Authors:  Harrys A Torres; George B McDonald
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

Review 10.  Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.

Authors:  Romeo-Gabriel Mihăilă
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.